How does The Genotype Network help M&A lawyers and Corporates close complex Life Sciences deals?
- Hanneke Later-Nijland
- Jun 9
- 1 min read
Updated: Jul 7
Strengthening Global M&A Support in Life Sciences
The Genotype Network (TGN) is a global alliance of leading Life Sciences Regulatory lawyers, purpose-built to support cross-border M&A transactions. TGN lawyers work closely with M&A teams around the world to provide specialist regulatory insight throughout the deal process.
In that context, Hanneke Later-Nijland, the founder of TGN, visited New York City during the IBA M&A week early June, in order to connect with international M&A lawyers.
Last year, TGN contributed to a €2.4 billion multi-jurisdictional transaction led by a US-based M&A team at a global law firm. Our deep industry knowledge — spanning jurisdictions including Italy, Germany, France, the UK, the Netherlands, and Australia — helped uncover key regulatory risks, ultimately enabling the client to negotiate a lower purchase price.
We’re excited to continue expanding our presence in key jurisdictions and look forward to supporting M&A teams — both in execution and in competitive pitch processes — with our regulatory expertise in pharma, biotech, and broader life sciences.
Next to this, The Genotype Network also supports Corporate M&A teams in executing Life Sciences acquisitions with regulatory confidence.
For more information, download our One-Pager for either M&A lawyers or Corporates here!
Comments